Troponin HsTnI as pronostic factor in Covid-19 patients : Mohammed VI Hospital University experience

Abstract

ABSTRACT Background Recent reports have demonstrated high troponin levels in patients affected with COVID-19. We sought in our study to determine the relationship between troponin levels and COVID-19 outcomes severity/mortality. Methods This was an observational retrospective cohort study of 325 patients admitted and diagnosed COVID-19 positive in Mohammed VI CHU in Oujda from July 2021 to November 2021 Results The mean age between deceased and cured patients (68.92 ± 15.06 vs 62.5 ± 15.73 years, respectively, p<0.001) but no significant difference in the sex ratio was found in the two groups (p 0.379). 191 on admission, had a measured troponin ≤26 whom 80.6% were hospitalized in covid unit, while 134 patients had a measured troponin > 26ng/ ml whom 56.5% were admitted in the ICU (p<0.001) 73% of patients with an admission troponin ≤26ng/L survived while 27% had deceased with p<0.001.Similarly, the measurement of serum Troponin at the of hospitalization was 73ng/L (25.6–319.6) while for discharged patients was 9.6 ng/L (4.3–31.7) The distribution of hs-TnI maximum value measured, showed a concentration significantly higher in the deceased patients vs survivors [200 ng/L IQR 48–651 vs 19 ng/L IQR 7.97–85.87, p<0.001]. Conclusion our study demonstrates that Troponin may be an indicator of severity and may contribute to determining the severity of patients infected with COVID-19. Utilising troponin measurements alongside with other clinical and laboratory variables can be used for identifying patients at higher risk of in-hospital mortality and there by predict the progression of COVID-19 towards a worse outcome and to assign for more stringent strategies of treatment